Table 1.

List of Inhibitors under study in vivo or in the clinic as anticancer therapeutics.

Categories	Compound	Target	Conditions	Clinical Trials	Clinical Trials Identifier/Ref.
Mitochondrial dynamics and function	βIIPKC inhibitor	MFN1	Heart failure	Experimental	[156,157]
	ONC201	Mitochondrial respiration	Multiple cancers	Several trials in process	[171]
NADH production	Gossypol	Aldehyde dehydrogenase	Multiple cancers	Several trials in process	[158]
Microtubule	Paclitaxel	β-Tubulin subunit	Multiple cancers	Several trials in process	[159,160]
	Colchicine	β-Tubulin subunit	Multiple cancers	Several trials in process	[161,162]
	Vinca alkaloid	Tubulin dimer	Multiple cancers	Several trials in process	[163,164]
Actin	Cytochalasin D	Actin monomer	Infertility	Preclinical	NCT03677492
	Phalloidin	F-actin	Depression	Preclinical recruiting	NCT04137458
	Y-27632	Rho-associated kinase	Hippocampal neurons	Preclinical	[165]
ETC	Metformin	Complex I	Multiple cancers	Several trials in progress	NCT03477162
	Phenformin	Complex I	Diabetes mellitus, type 2	Preclinical completed	NCT02475499
	Rotenone	Complex I	Parkinson’s disease	Preclinical enrolling	NCT04287543
	IM156	Complex I	Advanced solid tumor and lymphoma	Phase I active	NCT03272256
	3-NPA	Complex II	Parkinson’s disease	Preclinical	[166]
	Malonate	Complex II	Parkinson’s disease	Phase I terminated	NCT01476085
	TTFA	Complex II	Cancer	Experimental	[167]
	Atpenin A5	Complex II	Cardiac ischemia-reperfusion injury	Preclinical	[168]
	Lonidamine	Complex II	Symptomatic benign prostatic hyperplasia, enlarged prostate	Phase 2, 3 terminated	NCT00237536, NCT00435448
	Antimycin A	Complex III	Lung cancer	Experimental	[169]
	Cyanide	Complex IV	Malignant glioma	Phase 2 recruiting	NCT00075387
	Oligomycin	Complex V	Cancer cachexia, transthyretin amyloidosis	Preclinical recruiting	NCT03144128, NCT03328338
	GBOXIN	Complex V	Glioblastoma	Preclinical	[170]